A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)

NCT00654420 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

95

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-small-cell Lung

Interventions

DRUG: Dalotuzumab
DRUG: Erlotinib

Sponsor

Merck Sharp & Dohme LLC